Cempra (CEMP +3.6%) rises after getting a five year contract worth up to $58M to develop its...

|By:, SA News Editor

Cempra (CEMP +3.6%) rises after getting a five year contract worth up to $58M to develop its lead product candidate solithromycin (an antibiotic under development for the treatment of community-acquired bacterial pneumonia) for use in pediatrics and as a defense against bioterrorism. (PR)